EXEL vs RCUS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. EXEL and RCUS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined EXEL and RCUS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Exelixis, Inc. is a commercial-stage oncology company whose business is dominated by cabozantinib, sold in the United States as CABOMETYX. Cabozantinib is a tyrosine kinase inhibitor (TKI) approved across several cancers, most importantly advanced renal cell carcinoma (kidney cancer) and certain neuroendocrine tumors, and it is the market-leading TKI in second-line-plus kidney cancer. In the first quarter of 2026, cabozantinib captured roughly 47% of total TKI prescriptions in its core setting, up from about 44% a year earlier, and the franchise generated the large majority of company revenue. Unlike clinical-stage biotechs that burn cash, Exelixis is solidly profitable and returns capital through share buybacks.

Full EXEL guide

Arcus runs a single reportable segment out of Hayward, California with roughly 600 employees, and it has never generated revenue from product sales. Every dollar recognized since the 2018 IPO has come from research, collaboration and license arrangements, principally with Gilead Sciences and Japan's Taiho Pharmaceutical. Gilead paid $725 million in 2022 to license the anti-TIGIT program (domvanalimab and AB308), the adenosine receptor program (etrumadenant) and the CD73 program (quemliclustat), plus a further $100 million option continuation payment received in 2024. Taiho holds rights across Japan and much of Asia excluding China to five Arcus programs, exercised its casdatifan option in the fourth quarter of 2025 for $15 million, and became obligated in the second quarter of 2026 to pay a $30 million clinical milestone tied to the Phase 3 PEAK-1 study. Those payments sit in deferred revenue and are released to the income statement as Arcus performs the underlying research, so reported revenue tracks the pace of laboratory and trial work rather than any commercial activity. The portfolio itself has narrowed sharply. Gilead returned the etrumadenant license in 2025, three Phase 3 studies of domvanalimab have been stopped since December 2025, and casdatifan, which Arcus owns outright, is what remains.

Full RCUS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• EXEL drivers: Cabozantinib franchise growth; Zanzalintinib pipeline transition.
• RCUS drivers: Casdatifan carries the whole valuation; Gilead has stepped back without selling.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is single-franchise concentration: the large majority of revenue comes from cabozantinib, so any competitive, safety, or reimbursement setback in kidney cancer would hit the whole company. For RCUS, concentration is the central risk.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick EXEL if you believe its drivers more; RCUS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the EXEL and RCUS guides.

EXEL. Figures are approximate and tied to the asOf date, so verify live numbers before acting. Exelixis trades at a moderate biotech multiple that partly reflects its rare profitability, but that multiple embeds two big assumptions: that cabozantinib keeps growing into the patent cliff and that zanzalintinib successfully replaces it. Because so much value hinges on clinical and regulatory outcomes, the valuation is more sensitive to STELLAR trial data and the colorectal decision than to any single earnings print.

RCUS. Every conventional multiple here is either undefined or misleading. The ~33x trailing sales figure a screener prints rests on a revenue stream management has already guided down to $65 million to $75 million for 2026, with no commercial engine behind it. The ~$3.2 billion enterprise value instead represents a probability-weighted view of casdatifan in clear cell kidney cancer, a market Arcus sizes at $5 billion to $10 billion, discounted for Phase 3 risk and for the cash the company expects to consume between now and the second half of 2028.

Headline figures (approximate, July 2026): EXEL shows revenue (ttm) ~$2.2 billion (Q1 2026 total revenue was ~$611 million, up ~10% year over year), 2026 revenue guidance ~$2.525 to $2.625 billion total (net product ~$2.325 to $2.425 billion), non-gaap net income (q1 2026) ~$233 million (~$0.87 diluted per share, beating estimates), cash and marketable securities ~$1.65 billion, with a new ~$750 million buyback authorized; RCUS shows revenue (ttm) ~$117 million for the twelve months to June 30, 2026, versus $247 million in fiscal 2025 and $258 million in fiscal 2024. All of it is collaboration revenue from Gilead and Taiho; Arcus has never recorded product sales. Second-quarter 2026 revenue was $41 million against $160 million a year earlier, a 74% decline, because the prior-year quarter included $152 million of license and development services revenue recognized in one go., 2026 guidance and the deferred revenue behind it Management guides GAAP revenue of $65 million to $75 million for full-year 2026, which would be roughly a 70% decline from 2025. The deferred revenue balance that feeds the line stood at $56 million at June 30, 2026 ($19 million current and $37 million noncurrent), down from $78 million at December 31, 2025 and $319 million at December 31, 2024. Remaining performance obligations were disclosed at $256 million at the end of 2025., operating expenses R&D was $113 million in the second quarter of 2026 and $235 million for the half, down from $139 million and $261 million. G&A was $24 million and $53 million against $29 million and $57 million. Full-year 2025 R&D was $523 million and G&A $110 million. Partnership reimbursements offsetting R&D fell to $36 million for the half from $71 million, and late-stage program spend came in at $111 million versus $129 million., earnings and eps Net loss of $91 million, or $0.72 per share, in the second quarter of 2026, and $219 million, or $1.74 per share, for the first half on 125.7 million weighted-average shares. The trailing twelve-month loss is ~$460 million, or ~$3.86 per share. Fiscal 2025 produced a $353 million loss and fiscal 2024 a $283 million loss. Accumulated deficit stands at $1.704 billion. No P/E ratio exists and no income tax was recorded, given forecast full-year net operating losses..

EXEL and RCUS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined EXEL and RCUS exposure against your real portfolio. It is not an investment adviser.